Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:GHRS NASDAQ:HCM NASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.35+1.9%$6.84$4.25▼$9.85$2.72B0.484.75 million shs1.01 million shsGHRSGH Research$14.09+0.3%$14.18$6.00▼$20.50$733.07M0.97195,288 shs245,365 shsHCMHUTCHMED$15.97+7.6%$16.37$11.51▼$21.50$2.79B0.4556,157 shs68,834 shsNAMSNewAmsterdam Pharma$27.00+5.2%$22.98$14.06▼$27.29$3.04B-0.01806,032 shs1.57 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+1.80%-0.88%+27.63%+54.63%+18.09%GHRSGH Research+0.28%+4.37%+15.97%+12.72%+66.35%HCMHUTCHMED+7.61%+6.40%-10.88%+4.04%-8.32%NAMSNewAmsterdam Pharma+5.22%+12.27%+14.31%+34.06%+68.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.35+1.9%$6.84$4.25▼$9.85$2.72B0.484.75 million shs1.01 million shsGHRSGH Research$14.09+0.3%$14.18$6.00▼$20.50$733.07M0.97195,288 shs245,365 shsHCMHUTCHMED$15.97+7.6%$16.37$11.51▼$21.50$2.79B0.4556,157 shs68,834 shsNAMSNewAmsterdam Pharma$27.00+5.2%$22.98$14.06▼$27.29$3.04B-0.01806,032 shs1.57 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+1.80%-0.88%+27.63%+54.63%+18.09%GHRSGH Research+0.28%+4.37%+15.97%+12.72%+66.35%HCMHUTCHMED+7.61%+6.40%-10.88%+4.04%-8.32%NAMSNewAmsterdam Pharma+5.22%+12.27%+14.31%+34.06%+68.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0022.53% UpsideGHRSGH Research 2.88Moderate Buy$32.00127.11% UpsideHCMHUTCHMED 3.00Buy$28.0075.33% UpsideNAMSNewAmsterdam Pharma 2.90Moderate Buy$41.5553.87% UpsideCurrent Analyst Ratings BreakdownLatest GHRS, BHC, NAMS, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025NAMSNewAmsterdam PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.008/13/2025GHRSGH ResearchZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/11/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/7/2025NAMSNewAmsterdam PharmaRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$38.00 ➝ $39.007/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $28.007/17/2025NAMSNewAmsterdam PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$27.006/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$39.006/17/2025NAMSNewAmsterdam PharmaCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$42.006/12/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/10/2025NAMSNewAmsterdam PharmaStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.86B0.28$7.73 per share0.95($0.89) per share-8.25GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AHCMHUTCHMED$630.20M4.42$0.29 per share55.60$4.43 per share3.60NAMSNewAmsterdam Pharma$45.56M66.75N/AN/A$8.20 per share3.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2628.251.58N/A0.99%-852.36%5.25%10/29/2025 (Estimated)GHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0010.94N/AN/AN/AN/AN/ANAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)Latest GHRS, BHC, NAMS, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/A8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98GHRSGH ResearchN/A29.4929.49HCMHUTCHMED0.054.654.51NAMSNewAmsterdam PharmaN/A21.0821.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%GHRSGH Research56.90%HCMHUTCHMED8.82%NAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%GHRSGH Research41.60%HCMHUTCHMED3.60%NAMSNewAmsterdam Pharma20.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.35 million296.39 millionOptionableGHRSGH Research1052.03 million30.38 millionOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableGHRS, BHC, NAMS, and HCM HeadlinesRecent News About These CompaniesDuquesne Family Office LLC Grows Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMSSeptember 6 at 8:56 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 18,073 SharesSeptember 6 at 8:10 AM | insidertrades.comCutter Capital Management LP Sells 116,000 Shares of NewAmsterdam Pharma Company N.V. $NAMSSeptember 6 at 7:35 AM | marketbeat.comNewAmsterdam Pharma Company N.V. $NAMS Shares Purchased by Adage Capital Partners GP L.L.C.September 6 at 6:32 AM | marketbeat.comBVF Inc. IL Invests $1.21 Million in NewAmsterdam Pharma Company N.V. $NAMSSeptember 5 at 7:57 AM | marketbeat.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $41.55 Average Price Target from BrokeragesSeptember 5 at 2:53 AM | americanbankingnews.comNewAmsterdam Pharma Company N.V. $NAMS is RA Capital Management L.P.'s 5th Largest PositionSeptember 4 at 7:02 AM | marketbeat.comFrazier Life Sciences Management L.P. Raises Holdings in NewAmsterdam Pharma Company N.V. $NAMSSeptember 4 at 6:50 AM | marketbeat.comNewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3 at 11:04 PM | seekingalpha.comNewAmsterdam Pharma Company N.V. $NAMS Shares Purchased by Maverick Capital Ltd.September 3 at 7:29 AM | marketbeat.comOMERS ADMINISTRATION Corp Acquires 17,200 Shares of NewAmsterdam Pharma Company N.V. $NAMSSeptember 3 at 4:42 AM | marketbeat.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 3 at 3:26 AM | marketbeat.comInvesco Ltd. Sells 31,625 Shares of NewAmsterdam Pharma Company N.V. $NAMSSeptember 1, 2025 | marketbeat.comSiren L.L.C. Trims Stake in NewAmsterdam Pharma Company N.V. $NAMSAugust 31, 2025 | marketbeat.comPiramal Pharma completes multimillion-dollar upgrade to Bucks County plantAugust 29, 2025 | bizjournals.comNewAmsterdam Pharma Company N.V. $NAMS Holdings Lifted by American Century Companies Inc.August 29, 2025 | marketbeat.comLouise Frederika Kooij Sells 8,269 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockAugust 28, 2025 | insidertrades.comInsider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 50,000 Shares of StockAugust 27, 2025 | marketbeat.comWells Fargo & Company Initiates Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)August 27, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 50,000 Shares of StockAugust 26, 2025 | americanbankingnews.comJohannes Jacob Piete Kastelein Sells 50,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockAugust 26, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGHRS, BHC, NAMS, and HCM Company DescriptionsBausch Health Cos NYSE:BHC$7.34 +0.14 (+1.87%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$7.35 +0.00 (+0.07%) As of 09/5/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.GH Research NASDAQ:GHRS$14.09 +0.04 (+0.28%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$13.71 -0.38 (-2.69%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.HUTCHMED NASDAQ:HCM$15.97 +1.13 (+7.61%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$15.98 +0.01 (+0.09%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.NewAmsterdam Pharma NASDAQ:NAMS$27.00 +1.34 (+5.22%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$26.68 -0.32 (-1.20%) As of 09/5/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
